Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Fatigue is a critical health parameter in older adults and stroke patients and is associated with negative health outcomes. Current assessment tools predominantly focus on walking related fatigue, neglecting other activities of daily living (ADLs). This study aims to fill this gap by developing a standardized, laboratory-based fatigue protocol that includes a broader range of ADLs, providing a more comprehensive fatigue assessment that's in line with the WHO vision of healthy ageing.
The aim of this study is to evaluate a lab-based fatigue protocol and to unravel the relationship between physiological or movement data and perceived fatigue.
Participants will take part in three separate measurement moments, during which they will execute a performance task that induces fatigue. In addition, relevant sensors will be used to collect meaningful data.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| People post-stroke | Experimental | The intervention includes a stress test that induces progressive feelings of fatigue. |
|
| Older adults with sarcopenia | Experimental | The intervention includes a stress test that induces progressive feelings of fatigue. |
|
| Healthy individuals | Experimental | The intervention includes a stress test that induces progressive feelings of fatigue. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Performance test | Other | The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in the Ratings of Perceived Exertion throughout the protocol execution | The subjective feelings of fatigue will be evaluated through the Ratings of Perceived Exertion. This will be expressed verbally by the participant throughout the execution of the protocol. | Collected during all measurement moments (2-12 weeks). |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in muscle activity throughout the protocol execution | Muscle activity data (EMG) will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in heart rate (variability) throughout the protocol execution |
Not provided
Stroke survivors:
Inclusion Criteria:
Exclusion Criteria:
Older adults with sarcopenia:
Inclusion:
Exclusion:
Healthy individuals:
Inclusion:
Exclusion:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brubotics Rehabilitation Research Center | Jette | Brussels Capital | 1090 | Belgium |
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| D055948 | Sarcopenia |
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Cardiorespiratory data (Heart rate) will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. |
| Collected during all measurement moments (2-12 weeks). |
| Changes in oxygen saturation throughout the protocol execution | Oxygen saturation data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in electrodermal activity throughout the protocol execution | Electrodermal activity data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in muscle force myography throughout the protocol execution | Muscle force myography data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in skin temperature throughout the protocol execution | Skin temperature data (degrees Celsius) will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in motion data throughout the protocol execution | IMU data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in plantar pressure throughout the protocol execution | Plantar pressure distribution data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in gaze patter throughout the protocol execution | Eye tracking data will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| Changes in joint angles throughout the protocol execution | Kinematic data (degrees) will be collected continuously throughout the protocol execution. Data acquisition will occur in a synchronized manner. | Collected during all measurement moments (2-12 weeks). |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |